For CDNF, the next milestone is selection of the new formulation in H2’21, followed by pre-clinical safety and tox studies in H1’22 before a move back into the clinic potentially towards H2’22-H1’23e. HER-096 will remain in pre-clinical development before IND-enabling studies and tox studies can commence in H1’22.
Aktuellt
SENASTE
